+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ranolazine"

Angina Pectoris Medication Market - Global Forecast to 2030 - Product Thumbnail Image

Angina Pectoris Medication Market - Global Forecast to 2030

  • Report
  • August 2025
  • 182 Pages
  • Global
From
Anti-Ischemic Agents - Global Strategic Business Report - Product Thumbnail Image

Anti-Ischemic Agents - Global Strategic Business Report

  • Report
  • February 2026
  • 139 Pages
  • Global
From
Angina Pectoris Drugs Market Report 2025 - Product Thumbnail Image

Angina Pectoris Drugs Market Report 2025

  • Report
  • September 2025
  • 250 Pages
  • Global
From
From
Refractory Angina- Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Angina- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
From
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Ranolazine is a cardiovascular drug used to treat chronic angina. It works by increasing the amount of blood and oxygen that reaches the heart, reducing the amount of energy the heart needs to pump blood. It is also used to reduce the risk of recurrent chest pain in people with chronic angina. Ranolazine is available in both immediate-release and extended-release formulations. Ranolazine is a relatively new drug, and its use is still being studied. It is generally well-tolerated, with few side effects. Common side effects include headache, dizziness, nausea, and constipation. It is not recommended for people with certain medical conditions, such as liver or kidney disease. Ranolazine is marketed by several pharmaceutical companies, including GlaxoSmithKline, Sanofi, and Pfizer. It is also available as a generic drug. Generic versions of ranolazine are typically less expensive than brand-name versions. Show Less Read more